
Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
A June–September roundup spanning hepatitis research and surveillance data, FDA and ACIP policy moves, diet and diagnostics insights, and pipeline updates from screening innovations to HBV/HDV/HCV trials and approvals.
Longitudinal data suggest durable protection despite declining anti-HBs, questioning routine booster needs.






